We attempted in vivo gene transfection into the central nervous system (CNS) of non-human primates using the hemagglutinating virus of Japan (HVJ)-AVE liposome, a newly constructed anionic type liposome with a lipid composition similar to that of HIV envelopes and coated by the fusogenic envelope proteins of inactivated HVJ. HVJ-AVE liposomes containing the lacZ gene were applied intrathecally through the cisterna magna of Japanese macaques. Widespread transgene expression was observed mainly in the neurons.
Introduction
Despite the promising results in experimental animals, gene therapy has, so far, not been successful in clinical situations. As Leiden 1 pointed out, many gene delivery systems show only limited transgene expression in humans, unlike those in rodents. Difference in the transgene expression between humans and rodents might be responsible for the disparity and thus, more representative conditions of clinical situations are needed to evaluate the strategies for gene therapy. The non-human primate is the most suitable subject for preclinical studies of human gene therapy. Therefore, we evaluated the extent of gene transfection into the central nervous system (CNS) in non-human primate.
Gene transfection into the CNS using viral and chemical gene delivery vectors has been investigated for the purpose of protection against neuronal insults and degeneration. Infection with adenovirus (Ad), 2 adenoassociated virus (AAV), 3 herpes simplex virus1 [4] [5] [6] or lentivirus 7, 8 have resulted in the reasonable extent of gene transfection in the target regions of the CNS.
Chemical gene delivery reagents including conventional hemagglutinating virus of Japan (HVJ) liposomes and a cationic liposome-DNA complex have also been developed. 9, 10 This liposome-mediated gene delivery system has advantages over viral vectors because they can transfer expression cassettes of unlimited size. They do not replicate or recombine to form an infectious agent, and may not evoke the inflammatory or immune responses as reported in adenoviral vectors. 11, 12 
ever, its efficiency has not been satisfactory in vivo.
Recently HVJ-AVE liposome, a new anionic-type liposome with the envelope that mimics the human immunodeficiency virus (HIV), has been developed. 13 Based upon an in vivo trial, this vector has a higher efficiency of gene expression than conventional HVJ liposomes and is expected as one of the most useful tools for in vivo gene therapy. We previously tried the intrathecal administration of HVJ-AVE liposome-bcl-2 complex in rats, which successfully resulted in a diffuse gene transfection into the entire CNS. 14 In the present study, the efficiency of HVJ-AVE liposomes in the transfer of DNA into monkey CNS was evaluated by intrathecal injection through the cisterna magna in three Japanese macaques (Nos. 1, 2 and 3). Widespread gene transfection was seen over the CNS. A fourth Japanese macaque (No. 4) received the 'empty' HVJ-AVE liposome in the same manner to serve as a control. These results were compared with those obtained by stereotactic injection into the striatum of two Japanese macaques (Nos 5 and 6), which showed focal gene expression around the injection site. Both methods seemed to be useful for CNS gene therapy.
Results
Injection of HVJ-AVE liposome-lacZ into the cisterna magna (Table 1, Figure 1 ) In monkeys 1, 2 and 3, ␤-gal-positive cells were seen in many parts of the brain. The areas that exhibited the high transfection rates (mean ± s.d.) were: dentate nucleus (59.4 ± 9.1%), Purkinje cells of cerebellar vermis (47.9 ± 17.8%), trigeminal nucleus (45.6 ± 18.7%), cochlear nucleus (44.1 ± 0.8%), oculomotor nucleus (43.0 ± 7.9%), Labeling index of ␤-gal in the CNS after an intrathecal injection of HVJ-AVE liposome-lacZ (mean ± s.d.%, n = 5).
olive nucleus (42.1 ± 21.7%), hippocampus (37.2 ± 1.9%) and facial nucleus (29.0 ± 2.7%). The following areas exhibited only limited or no transgene expression: caudate nucleus (9.5 ± 5.4%), cerebellar cortex (4.2 ± 2.9%), putamen (3.0 ± 1.2%), frontal cortex (0.6 ± 1.6%), parietal cortex and occipital cortex (0%). High transgene expression was observed in the regions close to the cisterna magna, where the HVJ-AVE liposome was applied, 
-Gal expression in the brain after an intrathecal injection of HVJ-AVE liposome-lacZ complex. Broad ␤-gal expression was seen with X-gal staining (a, b, d, e, g and h). No ␤-gal expression was seen in the frontal cortex (i). The intrathecal injection of HVJ-AVE liposome containing no DNA resulted in no ␤-gal-positive cells (c, f). (a) Cerebellar vermis. Blue stained Purkinje cells were seen among the granular cell layer (×10). (b) Dentate nucleus (×20). (c) Cerebellar vermis, control study (administration with HVJ-AVE liposome carrying no DNA). (d) Hippocampus (×4). (e) Hippocampus (×40). (f) Hippocampus, control study (administration of HVJ-AVE liposome carrying no DNA (×4). (g) Upper cervical cord (×4). (h) Upper cervical cord (×10). (i) Frontal cortex (×4).
while limited gene expression was detected in more distant areas, where the liposome vehicles rarely reached. In monkey 4, ␤-gal positive cells were absent.
In the injection of HVJ-AVE liposomes into the cisterna magna of monkey CNS, we did not detect any lymphocyte infiltration and neural cell death.
Stereotactic injection (Figures 2 and 3)
In monkeys 5 and 6, which received HVJ-AVE liposomes stereotactically into the striatum, the high lacZ expressing cells were observed at the injected site (58.5 ± 7.1%; mean ± s.d.). The ␤-gal positive cells were noted in areas more than 10 mm rostral or caudal from the injection tract (Figure 2 ). High transgene expression was also observed in the frontal cortex. The ␤-gal-positive cells were rarely recognized in the temporal, parietal and occipital cortex, which were farther than 15 mm from the tract.
Despite the high transgene expression in the frontal cortex around the needle insertion, gene expression in the striatum was lower than expected (9.5 ± 5.4%; mean ± s.d.). The small leakage of the liposome mixture seen at the injection site might have been responsible for this limited extent of expression. 
Figure 2 Stereotactic injection of HVJ-AVE liposome-lacZ complex into the striatum assayed with X-gal (a-f). (a) Dense ␤-gal expression at the cortical incision (×4). (b) Refluxed HVJ-AVE liposome-lacZ was diffused and transfected into the cortex from the brain surface (×20). (c) ␤-Galpositive cells were seen in the deep cortical neurons, which suggests that the HVJ-AVE liposome penetrated into the cortex (×4). (d) High ␤-gal expression at the injection tract (×4). T: injection tract. (e)

Discussion
In the present study, widespread transfection of the lacZ gene into monkey CNS was achieved using the HVJ-AVE liposome by intrathecal injection through the cisterna magna. A high efficiency of gene transfection was seen in the medial temporal lobe, brainstem and cervical cord. On the other hand, the injection of HVJ-AVE liposome into the striatum caused high transfection efficiency only in the frontal lobe and striatum. The same procedure with HVJ-cationic liposome was examined by Mabuchi et al 15 in an experimental mouse with glioma. Only disseminated glioma cells in the cerebrospinal fluid space expressed the lacZ gene. LacZ transfection was absent in either the neuronal or glial cells. This difference between HVJ-AVE and HVJ-cationic liposomes may result from the inability of cationic liposomes to penetrate tissues because of both net positive charge and large size (approximately 700 nm in diameter). 13 In contrast, anionic type liposomes can penetrate into tissues, and have higher transfection efficiency in vivo. For the purpose of gene transfection into the CNS, some researchers [4] [5] [6] have used microinjection of defective herpes simplex virus into the rat CNS, but these attempts resulted in the gene expression in only a limited region adjacent to the injection sites. A detailed examination of the efficiency of transfection into the target cells has not been reported. Many researchers also used Ad and AAV. Ad is thought as one of the suitable gene vectors for in vivo delivery into the CNS, because it can be applied in high titer and delivers genes efficiently to the nonreplicating and replicating cells. However, its major limitations are its immunogenicity and cytotoxicity. It is known that Ad evokes nonspecific inflammation and antivector cellular immunity. 12 AAV causes less immunogenicity, but its efficiency of in vivo CNS transfection is significantly lower than that of Ad and other viral vectors. Transfection with HVJ-AVE liposome produced ␤-galpositive cells as far as 15 mm rostral and caudal to the injection site. We did not evaluate the stability of gene expression. However, there is evidence that transfected gene expression was sustained for at least 2 weeks in the mouse liver and for 1 month in mouse skeletal muscle. 13 Therefore, the HVJ-AVE liposome seems a promising new vector for the transfection of neurons into the CNS.
The reason why the HVJ-AVE liposome delivers genes into neuronal cells and not glial cells is still unclear. Lentivirus vectors, which are also based on the HIV virus, exhibit highly specific transfection into adult neurons. Blö mer et al explained this specificity by the presence of vesicular stomatitis virus (VSV)-G protein in the lentivirus envelope and the enhancer domain of the hCMV promoter in the neuron. The VSV-G protein can broaden the host cell specificity because it can be recognized by the G protein receptors widely expressed on the cell surface while the hCMV major immediate-early promoter (HCMV MIEP) expressed in neurons drives the expression of the transfected gene preferentially. 7, 16 These hypotheses may support, at least partially, our results of neuron-specific transfection. Our lacZ gene is under the control of the hCMV promoter and may exhibit preferential expression in neurons. Although HVJ does not possess the VSV-G protein in its envelope, the HN protein, which is present in the HVJ envelope, can bind to receptors in most mammalian cells. The envelope protein and the HCMV MIEP may also partly explain the specificity of the gene transfection of the HVJ-AVE liposome. This is the first study demonstrating extensive gene transfection in almost entire CNS of non-human primates. Our final goal is to establish a therapeutic strategy for brain protection in humans. Further studies will be focused on the function of the transfected gene, for example, anti-apoptotic gene over the ischemic brain.
Materials and methods
Animals
Six adult female Japanese macaques, ranging in age from 5 to 10 years and weighing from 4.75 to 7.80 kg, were used in the study. They were provided with a standard diet of monkey biscuits supplemented with fresh fruit.
HVJ-AVE liposome
The detailed preparation of HVJ-AVE liposomes has been described previously by Saeki et al. 13 Briefly, each lipid (9.75 mg of lipids) mixture was hydrated in 200 l of a balanced salt solution (BSS: 137 mm NaCl, 5.4 mm KCl, 10 mm Tris-HCl, pH 7.6) containing 100 g of plasmid DNA, conjugated with UV-inactivated HVJ and adjusted in 1.0 ml of BSS for intrathecal injections and 100 l of BSS for intrastriatal injections.
Plasmid DNA pcDNA3 (Invitrogen, Leek, The Netherlands), containing the cytomegalovirus (CMV) promoter (655 bp), was restricted with HindIII-BamHI. The Escherichia coli ␤-gal gene, isolated from the pSV-␤-gal vector (Promega, Madison, WI, USA) by restriction with HindIII-BamHI and contains the SV40 nuclear transport signal in its N-terminus, was cloned into the restricted pcDNA3 (CMVlacZ).
In vivo gene transfer Monkeys 1, 2 and 3 were anesthetized with pentobarbital sodium (50 mg/kg). HVJ-AVE liposome containing the lacZ gene in BSS (1.0 ml) with 1 mm CaCl 2 was injected into the cisterna magna of the monkeys using a 1 ml syringe with a 23-gauge needle. Monkey 4 received 1.0 ml of HVJ-AVE liposome containing no DNA using the same procedure.
The other monkeys received HVJ-AVE liposome stereotactically into their striatum (monkeys 5 and 6). Each monkey was placed and fixed in a stereotactic apparatus, and a burr hole was made in the skull at a point 18 mm anterior to the external meatus and 9 mm lateral to the left of the midline. The dura mater was carefully cut in a cruciate manner and the pia mater was coagulated under the operating microscope. The needle was inserted vertically 22 mm from the brain surface, and HVJ-AVE liposome containing lacZ (100 l) was injected at a speed of 5 l/min into the left striatum. No specific symptoms, including weight loss or loss of activity, were seen in any of the monkeys after administration of the HVJ-AVE liposome.
Histologic examination
Seven days after transfection, the monkeys were anesthetized with an overdose of ketamine and pentobarbital sodium, and perfused with 4% paraformaldehyde and 0.1% glutaraldehyde in phosphate-buffered saline (PBS) (500 ml/kg). The brains were removed and placed in 30% sucrose in PBS for several days. After the meninges were carefully removed under the stereomicroscope, 40-mthick frozen serial sections were made in the frontal plane.
To detect transgene ␤-gal expression in the brain, the sliced brain sections were rinsed three times with PBS, and stained in X-gal buffer (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal, 0.5 mg/ml), 3 mm K 3 Fe (CN) 6 , 3 mm K 4 Fe (CN) 6 3H 2 O, 1 mm MgCl 2 , 10 mm KCl, 0.1% Triton X-100 in 0.1 m sodium phosphate buffer, pH 7.5) at 37°C for 8 h and counterstained with hematoxylin. The efficiency of gene transfection was evaluated by counting the blue staining cells in five random high power (×100) fields of five slides in each part of the CNS of monkey 1, 2 and 3 (intrathecal injection). The averaged percentages of transgene expression were calculated by counting blue staining cells in 1000 hematoxylin positive cells in each part of the CNS per monkey.
The character of the transfected cells was determined by immunohistochemistry using neurofilament as a marker for neuronal cells and glial fibrillary acidic protein (GFAP) as a marker for astrocytes. X-gal-stained slices were treated with 0.3% hydrogen peroxidase in methanol for 20 min to inactivate any endogenous peroxidase. They were then incubated with 1% normal horse and goat serum for 10 min, followed by an overnight incubation at 4°C with monoclonal anti-neurofilament antibody (SMI 32; Sternberger Monoclonals, Lutherville, MD, USA) and polyclonal anti-GFAP antibody (PC10555; Progen Biotechnik, Heidelberg, Germany). The sections were washed three times in PBS, incubated with a second antibody (1:400; Vector Laboratories, Burlingame, CA, USA) for 1 h, and then incubated for 1 h with avidinbiotin-horseradish peroxidase complex (Vector Laboratories). The histochemical localization of HRP was visualized with 3,3Ј-diaminobenzidine (DAB) and hydrogen peroxide. Ten slides were collected around the injection site of CNS of monkey 5 and 6 (stereotactic injection) and the percentage of double staining cells with X-gal and antineurofilament antibody or anti-GFAP antibody were calculated by counting 1000 blue staining cells per monkey.
All animal care and experimental procedures were in accordance with the NIH Guide for the Care and Use of Laboratory Animals (1996) and approved by the Animal Experiment Committee of Graduate School of Medicine, Osaka University.
